Cantor Fitzgerald Reiterates Overweight Rating for Bicara Therapeutics (NASDAQ:BCAX)

Bicara Therapeutics (NASDAQ:BCAX)‘s stock had its “overweight” rating reaffirmed by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $13.01 target price on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 0.08% from the stock’s current price.

A number of other equities research analysts have also issued reports on the stock. Wedbush reaffirmed an “outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a report on Wednesday, February 12th. HC Wainwright upped their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $36.50.

Bicara Therapeutics Price Performance

Shares of NASDAQ:BCAX traded down $0.01 during trading on Thursday, reaching $13.00. The stock had a trading volume of 265,748 shares, compared to its average volume of 426,274. Bicara Therapeutics has a 1-year low of $11.10 and a 1-year high of $28.09. The stock has a fifty day moving average of $13.35.

Hedge Funds Weigh In On Bicara Therapeutics

Large investors have recently modified their holdings of the business. RA Capital Management L.P. purchased a new stake in Bicara Therapeutics in the 3rd quarter valued at about $177,169,000. Red Tree Management LLC purchased a new stake in shares of Bicara Therapeutics in the 4th quarter valued at approximately $55,230,000. FMR LLC acquired a new position in shares of Bicara Therapeutics in the 3rd quarter worth approximately $57,913,000. Braidwell LP purchased a new position in shares of Bicara Therapeutics during the 3rd quarter worth approximately $42,219,000. Finally, Adage Capital Partners GP L.L.C. increased its holdings in Bicara Therapeutics by 171.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company’s stock valued at $37,893,000 after purchasing an additional 1,375,265 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.